News

Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing

Published on 19/08/2021
Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing

Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services (‘YGS’) has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).

In April 2021, the Company announced it was successful in securing tenders under Public Health England’s National Microbiology Framework for Lots 1-4 and was one of only three companies to successfully be awarded all four Lots. This meant public health authorities across the UK were able to issue call-off contracts to procure goods and testing services from Yourgene.

This contract is the first to come of the National Microbiology Framework Lot wins announced earlier this year, using Yourgene’s high throughput automated COVID-19 services testing laboratory in Citylabs 1.0, Manchester. The final contract notice value is the maximum estimated value of the contract. Actual value will depend on services purchased. There is no committed spend.

Lyn Rees, Chief Executive Officer, commented: “We are delighted to have been awarded this first contract from the framework, supporting the Government’s testing needs utilising our recently completed high throughput COVID-19 diagnostic testing laboratory.”

This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

Our Valued Sponsors & Partners